DNA Damage Response Signaling
See how Bayer is investigating DNA damage response signaling across the oncology pipeline
Explore the investigational compounds, tumor types, and clinical trials associated with this area of research.
DNA Damage Response Signaling
The DNA damage response (DDR) is a network of signaling pathways that detect DNA damage and coordinate cellular responses to maintain genomic integrity1,2
DNA damage can arise from normal cellular processes such as DNA replication and metabolism, as well as from external stressors including radiation and chemotherapeutic agents1,3
Key DDR kinases are activated by DNA damage and regulate checkpoint signaling and DNA repair pathways1
Defects in DDR signaling can lead to genomic instability, a hallmark of cancer that promotes tumor development and progression1,2
Tumors with alterations in DDR pathways may rely on alternative repair mechanisms, creating opportunities for targeted therapies that exploit synthetic lethal interactions1
Bayer’s Oncology Pipeline Brochure
Explore a comprehensive overview of Bayer's oncology pipeline, including investigational compounds, clinical trials, and areas of research.
The ongoing clinical trials listed on this website represent a comprehensive overview of Bayer's clinical pipeline in Oncology, including Bayer-sponsored research and collaborative research with academic centers, cooperative groups, and other global institutions.